Table S2 presents the key characteristics of the included patients. The included studies examine practically all types of TRAEs across 16 different cancer types. We grouped the included studies based on targeted immune checkpoint type: anti-CTLA-4, anti-PD-1, and anti-PD-L1. Table S2 shows the number of people using different ICI drugs (PD-1 inhibitor: 18,854 patients, PD-L1 inhibitor: 4,858 patients, CTLA-4 inhibitor: 2,565 patients). Here, PDCD1 is linked to cancer.